Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

Kai-Xin Yao1,6, Hang Lyu2,6, Mei-Hua Liao3, Lin Yang3, Yin-Ping Gao3, Qi-Bing Liu5, Cheng-kun Wang2, Ying-Mei Lu3, Guo-Jun Jiang4*, Feng Han2* & Ping Wang1*

Vascular dementia (VaD) is a complex disorder caused by reduced blood flow in the brain. However, there is no effective pharmacological treatment option available until now. Here, we reported that low-dose levamlodipine besylate could reverse the cognitive impairment in VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO). Oral administration of levamlodipine besylate (0.1 mg/kg) could reduce the latency to find the hidden platform in the MWM test as compared to the vehicle group. Furthermore, vehicle-treated mice revealed reduced phospho-CaMKII (Thr286) levels in the hippocampus, which can be partially restored by levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) treatment. No significant outcome on microglia and astrocytes were observed following levamlodipine besylate treatment. This data reveal novel findings of the therapeutic potential of low-dose levamlodipine besylate that could considerably enhance the cognitive function in VaD mice.

Results

Levamlodipine Besylate restores spatial learning and memory in VaD mice. In the present study, we investigated the pharmacological outcome of low-dose levamlodipine besylate on hypoperfusion-induced VaD. Levamlodipine was often used at the dose of 0.05 mg/kg on patients in clinical research18. According to the guide for dose conversion between animals and human, relevant papers choose the dosage of 1 mg/kg in

---

1College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China. 2College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China. 3School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China. 4Department of Pharmacy, Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China. 5School of Pharmacy, Hainan Medical College, Haikou, China. 6These authors contributed equally: Kai-Xin Yao and Hang Lyu. *email: jguojun999@163.com; changhuahan@zju.edu.cn; wangping45@zjut.edu.cn
Considering the eight-week chronic administration for mice, we select the dose of 0.1 mg/kg and 0.5 mg/kg in this study. Compared with sham-operated mice, the escape latency to find the hidden platform during training trials was significantly impaired in the vehicle-treated rUCCAO mice ($P < 0.05$). Notably, levamlodipine besylate’s attenuation to this cognitive dysfunction was observed in mice after daily repeating administration of levamlodipine at the doses of 0.1 mg/kg (Fig. 1).

In the novel object recognition (NOR) task, vehicle-treated rUCCAO mice showed a reduced ability to discriminate familiar object from novel one compared with sham mice (Fig. 2). By contrast, for the levamlodipine besylate (0.1 or 0.5 mg/kg)-treated rUCCAO mice, a significant improvement of cognitive function was observed, as revealed by significantly elevated exploring time (Fig. 2a) and exploring frequency (Fig. 2b) on different objects as compared to vehicle-treated mice.

Levamlodipine besylate prevents the dephosphorylation of CaMKII in rUCCAO mice. We, therefore, investigated some representative biochemical events to support the behavioral observations above. CaMKII is localized subcellular to the dendrites and the postsynaptic densities of excitatory synapses, and its phosphorylation was measured as a significant mediator of learning and memory\textsuperscript{20}. Here, immunofluorescence staining was performed to further confirm the outcome of levamlodipine besylate on phospho-CaMKII (Thr286) expression in the hippocampal region in rUCCAO mice. As revealed in Fig. 3a, a major decrease in the intensity of fluorescence for phospho-CaMKII (Thr286) in cornu ammonis 1 (CA1) pyramidal neurons of the hippocampus in vehicle mice compared with the sham-operated group. By contrast, levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) restored this decrease (Fig. 3a,b). In addition, memantine (20 mg/kg) could also restore the decrease, indicating that memantine might improve the cognitive dysfunction in VaD mice.
Effect of levamlodipine besylate on blood vessels in rUCCAO mice. Brain vascular deficit contributes to the progress of VaD. Here, we observed no obvious changes in vascular structure between sham and vehicle group (Fig. 4a). Levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) or memantine (20 mg/kg) treatment also did not have effect on their structure (Fig. 4a). There were also no differences in blood pressure among all groups (Fig. 4b).

Effect of levamlodipine Besylate on astrocyte activation in rUCCAO mice. Accumulating evidence showed that astrocytes were activated during the pathological process of VaD. Here, we observe a dramatic activation of astrocytes, as indicated by the elevation of GFAP expression. The data demonstrated that there was no significant inhibitory effect on astrocytes activation following levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) or memantine (20 mg/kg) treatment (Fig. 5). To extend our observations on astrocytes activation, we tested the total number of astrocytes by using S100β, an astrocytes marker. A similar result was also observed in CA1 regions of the hippocampus (Fig. 5).

Effect of levamlodipine besylate on microglia in rUCCAO mice. Microglia-induced neurotoxicity may contribute to the development of neurodegeneration in response to pathological signals by stimulating morphological changes and the production of a wide array of inflammatory cytokines. We further explore the effect of levamlodipine besylate on microglia in rUCCAO mice. Unlike a sham-operated group, our data revealed that the number of Iba-1 expressed cells in the hippocampus CA1 region of vehicle group was considerably increased. Here, levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) or memantine (20 mg/kg) treatment did not significantly attenuated rUCCAO-induced microglia activation in the hippocampus (Fig. 6).

Discussion

Brain hypoperfusion consequently results in a defect of learning and memory. In the present study, we revealed that hypoperfusion mediated dephosphorylation of CaMKII contributes to cognitive dysfunction, which can be rescued by levamlodipine besylate treatment. Overall, our findings add further support to the anti-dementia effect of levamlodipine besylate observed during behavioral and biochemical studies.

Importantly, low-dose levamlodipine besylate results in reduced neurological dysfunction after VaD. Several studies suggest that low-dose memantine could block the mild N-methyl-D-aspartate (NMDA) receptor and therefore improved working memory related to a highly challenging task in naive rats. However, the use of high dose NMDA receptor antagonists, such as memantine and MK-801, could impair the cognitive function. Therefore, the low-dose levamlodipine besylate might be suitable for VaD treatment, might be due to less effect on the blood pressure. Blood pressure reduction seems not to play a role in preventing dementia, indicating a direct protecting impact on neurons. Optimization of CCBs for the management of dementia may involve enhancement of the affinity and an increase of selectivity for presynaptic calcium channels to the inactivated state.

CaMKII is widely disseminated in the brain and a key mediator of physiological excitatory glutamate signals underlying long-term potentiation (LTP) induction and maintenance. Compared with behavior task, we suggested that dephosphorylation of CaMKII at Thr286 is a more sensitive indicator of learning and memory impairment. In the present study, we found that levamlodipine besylate (at the dose of 0.1 mg/kg and 0.5 mg/kg) could reverse the auto-phosphorylation of CaMKII at threonine 286 in CA1 regions of the hippocampus. The activation of CaMKII signaling contributes to the development of hypoperfusion-induced memory and learning deficits. A surplus of intracellular calcium is harmful to neuronal function. Therefore, these results suggest that low-dose levamlodipine besylate could considerably improve the cognitive dysfunction in VaD mice. We recently reported that calmodulin inhibitor somewhat introverted the dephosphorylation of CaMKII and synapsin I and amplified the number of mature neurons in the hippocampus, which associated with a major improvement in cognitive dysfunction in VaD mice.
Whereas the present study has provided helpful information about the effect of low-dose levamlodipine besylate in the management of VaD, but it has several limitations that must be acknowledged. This study offered little details on toxicity pieces of evidence of high dosage levamlodipine besylate in the present context. We were unable to conduct various trails with a different length of time for levamlodipine besylate treatment. This suggests the need for a multi-faceted and combination design, perhaps including more extensive time frame and animal models in dementia settings. The design of more potent and selective CCBs with a high level of state dependency may open avenues for new antidementive medication.

Materials and Methods

Chemicals. All chemical reagents were obtained from Sigma-Aldrich (St. Lou with an average molecular is, MO, USA) except as otherwise stated. Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Ethics statement. All experimental procedures and animal handling protocols were conducted according to the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. These procedures were approved by the Committee for Ethics of Animal Experiments at the Zhejiang University, China.

Animal model of rUCCAO. The rUCCAO model was prepared as previously reported15. Animals were divided into five groups. First, mice were anesthetized with chloral hydrate (400 mg/kg) and through mid-line cervical incision, the right common carotid artery (CCA) was isolated from the adjacent vagus nerve and double-ligated with 6–0 silk sutures. Sham-operated mice were subjected to the same surgical procedure without carotid ligation. After the operation, the mice were kept in their quarters with food and water available ad libitum. Eight weeks after operation, Levamlodipine Besylate was administered orally (p.o.) at 0.1 or 0.5 mg/kg respectively.
to the group of LAB 0.1 mg or LAB 0.5 mg, and Mementine was administered orally (p.o.) at a dose of 20 mg/kg to the group of MEM 20 mg. Sham and Vehicle group were administered saline orally. All the drugs were dissolved in saline. Drugs were administering once a day for eight weeks.

**Behavioral tests.** The novel object recognition test (NORT) was used to evaluate recognition memory. Briefly, mice were individually habituated to an open field box (35 × 25 × 35 cm) for two consecutive days. The experimenter who scored the behavior was blind to the treatment. Discrimination index was evaluated by comparing the difference between the time of exploration of the novel and familiar object and the total time spent on exploring both objects, which made it possible to adjust for differences in total exploration time.
Acquisition of the spatial learning task was performed over 4 consecutive days of testing as previously reported using the Morris water maze Task. The mouse was guided to the platform by the experimenter. The mouse spent another 10 s on the platform before it was picked up and placed back in the home cage. The day before the first day of formal test, pre-training sessions consisting of four trials (trial intervals of 45–60 min) were performed using a visible platform to exclude visual deficient mice. On the fifth day, each mouse was tested in a probe trial by removing the platform from the pool. The data were processed and analyzed for each acquisition trial or probe trial as the escape latency (in seconds) and the times of platform crossing (in numbers) time in the target quadrant (in seconds).

**Immunohistochemical staining and analysis.** After behavior test, animals were intracardially perfused with PBS followed by 4% PFA as previously described. Briefly, the brain sections were cut and incubated at room temperature in PBS with 0.01% Triton X-100 for 30 min and followed by blocking with 3% bovine serum albumin for 1 h. For immunolabeling, brain slices were probed with primary antibody overnight at 4°C. Antibodies included phospho-CaMKII (Thr286) (1:200), laminin, GFAP, OX-42, and S100β (1:500, Millipore, U.S.A). Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole) (Sigma-Aldrich, U.S.A.). After washing, the sections were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor 594-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA). Signals were visualized by using a Zeiss LSM 510 confocal microscope. The relative fluorescence intensity of immunostaining was quantified by using Image J software (NIH, Bethesda, MD, USA).

**Statistical analysis.** The data were presented as the mean ± S.E.M. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Tukey’s test for multigroup comparisons. P < 0.05 indicated statistically significant differences.

Received: 14 September 2017; Accepted: 20 May 2019;
Published online: 03 December 2019

**References**

1. O’Brien, J. T. et al. Vascular Cognitive Impairment. *Lancet Neurol.* 2, 89–98 (2003).
2. Hachinski, V. et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. *Stroke.* 37, 2220–2241 (2006).
3. Moorhouse, P. & Rockwood, K. Vascular Cognitive Impairment: Current Concepts and Clinical Developments. *Lancet Neurol.* 7, 246–253 (2008).
4. Doubal, F. N. et al. Big Data and Data Repurposing - Using Existing Data to Answer New Questions in Vascular Dementia Research. *BMC Neurol.* 17, 72 (2017).
5. Erkinjuntti, T. & Gauthier, S. The Concept of Vascular Cognitive Impairment. *Front Neurol Neurosci.* 24, 79–85 (2009).
6. Hill, J., Fillit, H., Shah, S. N., Del, V. M. & Futterman, R. Patterns of Healthcare Utilization and Costs for Vascular Dementia in a Community-Dwelling Population. *J. Alzheimers Dis.* 8, 43–50 (2005).
7. Qiao, H. et al. Propofol Affects Neuregeneration and Neurogenesis by Regulation of Autophagy Via Effects On Intracellular Calcium Homeostasis. *Anesthesiology.* 127, 490–501 (2017).
8. Lazarevic, V. et al. Physiological Concentrations of Amyloid Beta Regulate Recycling of Synaptic Vesicles Via Alpha7 Acetylcholine Receptor and Gd3+/Calcineurin Signaling. *Front Mol Neurosci.* 10, 221 (2017).
9. Lu, L., Wu, Z. Y., Li, X. & Han, F. State-of-the-art: functional fluorescent probes for bioimaging and pharmacological research. *Acta Pharmacologica Sinica* 39, 6–11 (2018).
10. Eckert, A. et al. Changes of Intracellular Calcium Regulation in Alzheimers Disease and Vascular Dementia. *J Neural Transm Suppl.* 54, 201–210 (1998).
11. Nimmrich, V. & Eckert, A. Calcium Channel Blockers and Dementia. *Br J Pharmacol.* 169, 1203–1210 (2013).
12. Scriabine, A. & van den Kerckhoff, W. Pharmacology of Nimodipine. A Review. *Ann N Y Acad Sci.* 522, 698–706 (1988).
13. Wang, X. J. et al. Endogenous Polysaccharide Based Micelles for Calmodulin Antagonist Delivery Against Vascular Dementia. *ACS Appl Mater Interfaces.* 8, 35045–35058 (2016).
14. Hu, M. et al. Nimodipine Activates Neuroprotective Signaling Events and Inactivates Autophages in the Vcid Rat Hippocampus. *Neuro Res.* 1–6 (2017).
15. Qu, Z. et al. Pre-Treatment with Nimodipine and 7.5% Hypertonic Saline Protects Aged Rats Against Postoperative Cognitive Dysfunction Via Inhibiting Hippocampal Neuronal Apoptosis. *Behav. Brain Res.* 321, 1–7 (2017).
16. Goldmann, S., Stohlfeuss, J. & Born, L. Determination of the Absolute Configuration of the Active Amlodipine Enantiomer as (−)-S: A Correction. *J. Med. Chem.* 35, 3341–3344 (1992).
17. Wang, R. X., Jiang, W. P., Li, X. R. & Lai, L. H. Effects of (S)-Amlodipine and (R)-Amlodipine On L-Type Calcium Channel Current of Rat Ventricular Myocytes and Cytosolic Calcium of Aortic Smooth Muscle Cells. *Pharmacaz.* 63, 470–474 (2008).
18. Elliott, W. J. & Bistrika, E. A. Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. *Expert opinion on drug safety* 17, 207–216 (2018).
19. Yang, Y. L. et al. Synergic effects of levalumab and bisoprolol on blood pressure reduction and organ protection in spontaneously hypertensive rats. *CNS Neuroscience & Therapeutics.* 18, 471–474 (2012).
20. Lu, N. N. et al. Cholinergic Ghr2-Associated-Binding Protein 1 Regulates Cognitive Function. *Cereb. Cortex.* 1–4 (2017).
21. Sudduth, T. L. et al. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. *Journal of Cerebral Blood Flow & Metabolism.* 33, 708–715 (2013).
22. Ma, J. et al. Protective Effect of Carnosine On Subcortical Ischemic Vascular Dementia in Mice. *CNS Neurosci. Ther.* 18, 745–753 (2012).
23. Lu, Y. M. et al. P2X7 Signaling Promotes Microscope Embolism-Triggers Microglia Activation by Maintaining Elevation of Fas Ligand. *J Neuroinflammation.* 9, 172 (2012).
24. El, M. A., Petridis, A. K. & Rutishauser, U. Use of Polysaccharide Acid in Repair of the Central Nervous System. *Proc Natl Acad Sci USA* 103, 16989–16994 (2006).
25. Kakefuda, K., Ishioka, M., Tsuruma, K., Shimazawa, M. & Har, H. Memantine, an Nmda Receptor Antagonist, Improves Working Memory Deficits in Dgkbeta Knockout Mice. *Neurosci. Lett.* 630, 228–232 (2016).
26. Duda, W. et al. Mk-801 and Memantine Act Differently On Short- Term Memory Tested with Different Time-Intervals in the Morris Water Maze Task. *Behav. Brain Res.* 311, 15–23 (2016).
27. Wesierska, M. J., Duda, W. & Dockery, C. A. Low-Dose Memantine-Induced Working Memory Improvement in the Allothetic Place Avoidance Alternation Task (Asapat) in Young Adult Male Rats. *Front. Behav. Neurosci.* **7**, 203 (2013).
28. Coultrap, S. J., Vest, R. S., Ashpole, N. M., Hudmon, A. & Bayer, K. U. Camkii in Cerebral Ischemia. *Acta Pharmacol. Sin.* **32**, 861–872 (2011).
29. Moriguchi, S. *et al.* Nefiracetam Activation of Cam Kinase Ii and Protein Kinase C Mediated by Nmda and Metabotropic Glutamate Receptors in Olfactory Bulbectomized Mice. *J. Neurochem.* **110**, 170–181 (2009).
30. Fukunaga, K. & Miyamoto, E. A Working Model of Cam Kinase Ii Activity in Hippocampal Long-Term Potentiation and Memory. *Neurosci. Res.* **38**, 3–17 (2000).
31. Tan, C. *et al.* Endothelium-Derived Semaphorin 3G Regulates Hippocampal Synaptic Structure and Plasticity via Neuropilin-2/ PlexinA4. *Neuron* **101**, 920–937 (2019).
32. Yamamoto, Y. *et al.* Nobiletin Improves Brain Ischemia-Induced Learning and Memory Deficits through Stimulation of Camkii and Creb Phosphorylation. *Brain Res.* **1295**, 218–229 (2009).
33. Min, D. *et al.* Donepezil Attenuates Hippocampal Neuronal Damage and Cognitive Deficits After Global Cerebral Ischemia in Gerbils. *Neurosci. Lett.* **510**, 29–33 (2012).
34. Dong, Y., Kalueff, A. V. & Song, C. N-Methyl-D-Aspartate Receptor-Mediated Calcium Overload and Endoplasmic Reticulum Stress are Involved in Interleukin-1Beta-Induced Neuronal Apoptosis in Rat Hippocampus. *J. Neuroimmunol.* **307**, 7–13 (2017).
35. Cheng, P. *et al.* Chronic cerebral ischemia induces downregulation of A1 adenosine receptors during white matter damage in adult mice. *Cellular and molecular neurobiology.* **35**, 1149–1156 (2015).
36. Wang, X. J. *et al.* Endogenous polyacrylic acid based micelles for calmodulin antagonist delivery against vascular dementia. *Acs Applied Materials & Interfaces.* **51**, 35–45 (2016).
37. Wang, H. *et al.* P2RX7 Sensitizes Mac-1/Icam-1-Dependent Leukocyte-Endothelial Adhesion and Promotes Neurovascular Injury During Septic Encephalopathy. *Cell Res.* **25**, 674–690 (2015).
38. Wang, R. *et al.* Calmodulin inhibitor ameliorates cognitive dysfunction via inhibiting nitrosative stress and Nlrp 3 signaling in mice with bilateral carotid artery stenosis. *CNS neuroscience & therapeutics.* **23**, 818–826 (2017).
39. Tian, Y. *et al.* Melatonin Reverses the Decreases in Hippocampal Protein Serine/Threonine Kinases Observed in an Animal Model of Autism. *J. Pineal Res.* **56**, 1–11 (2014).
40. Zhu, X. *et al.* (-)-Scr1693 Protects Against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat Model. *Sci Rep.* **6**, 28908 (2016).

**Acknowledgements**

This work was supported by the National Natural Science Foundations of China (81573411), Zhejiang Provincial Natural Science Foundation of China (Y18H310026).

**Author Contributions**

H.L., M.H.L., L.Y., Y.P.G. and K.X.Y. led the major experiments and data analysis. Q.B.L., C.K.W. and Y.M.L. analyzed the data and drafted the manuscript. P.W., G.J.J. and F.H. jointly supervised this work and revised the manuscript critically. All authors read and approved the final manuscript.

**Competing Interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to G.-J.J., F.H. or P.W.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2019